ART score prognostic significance in patients with intermediate hepatocellular carcinoma
Authors:
MUDr. Petr Hříbek; MUDr. Kristýna Kubíčková; MUDr. Hana Parobková; Ing. Ph.D. Nikola Kaspříková; prof. MUDr. Petr Urbánek Csc
Authors‘ workplace:
Interní klinika 1. LF UK a ÚVN Praha: U Vojenské nemocnice 1 00, Praha 6, 169 0
1; Radiodiagnostické oddělení ÚVN Praha: U Vojenské nemocnice 1200, Praha 6, 169
2; Oddělení biomedicínské statistiky 1. LF UK Praha
3
Published in:
Čas. Lék. čes. 2016; 155: 52-55
Category:
Original Article
Overview
Palliative transarterial chemoembolization is indicated for patients with stage B hepatocellular carcinoma (HCC) based on the Barcelona Clinic Liver Cancer classification (BCLC). As this is a very wide and heterogenous group of patients, the ART score was designed to better differentiate these patients and to guide the decision for a second transarterial chemoembolization cycle.
The goal of the study is to prove that the ART score is appropriate to define subgroups within the stage BCLC-B HCC group with significantly better or worse overall survival (OS) after repeated transarterial chemoembolization. A combined retrospective and prospective study was performed of the OS of patients with stage BCLC-B HCC that were monitored and treated at the Internal Medicine Clinic of the First Faculty of Medicine, Charles University in Prague and the Central Military Hospital Prague. An analysis of the survival curve using the Kaplan-Meier method was performed using the R software package.
The median OS of the entire patient group was 18 months (95% CI 12–33). The median OS of patients with a favorable ART score was 33 months (95% CI 12–33) compared to 12 months (95% CI 6–18) for patients with an unfavorable ART score. The difference in OS in the subgroups differentiated by ART score was statistically significant (p < 0.01). Due to the significant difference in OS of patients differentiated by ART score, the currently recommended guidelines for the treatment of patients with stage BCLC-B hepatocellular carcinoma should be revised.
Keywords:
hepatocellular carcinoma, transarterial chemoembolization, cirrhosis
Sources
1. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of Hepatocellular Carcinoma: An Update. Hepatology 2010 July; Dostupné na: http://www.aasld.org/practiceguidelines 2010
2. Llovet JM et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734–1739.
3. Vogl TJ, Naguib NN, Nour-Eldin NE et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 2009 Dec; 72(3): 505–516; doi: 10.1016/j.ejrad.2008.08.007.
4. Malagari K. Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC bead. Expert Rev Anticancer Ther 2008; 8(10): 1643–1650.
5. Lammer J, Malagari K, Vogl T et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33(1): 41–52; doi: 10.1007/s00270-009-9711-7.
6. Sieghart W, Hucke F, Pinter M et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013 Jun; 57(6): 2261–2273; doi: 10.1002/hep.26256.
7. Bolondi L, Burroughs A, Du
8. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 Mar-Apr; 55(2): 74–108.
9. four JF et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012; 32: 348–359
10. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–943.
11. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010 Feb; 30(1): 52–60; doi: 10.1055/s-0030-1247132.
12. Bruix J et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012; 57: 821–829.
13. Llovet JM, Ricci S, Mazzaferro V et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 Jul 24; 359(4): 378–390; doi: 10.1056/NEJMoa0708857.
14. Wang Z, Zhou W, Zhang H, Qiao L. Combination of anti-angiogenesis agents and transarterial embolization: Is it a promising approach for the treatment of liver cancer? Discov Med 2015 Aug; 20(108): 51–55.
15. Carr BI. Some new approaches to the management of hepatocellular carcinoma. Semin Oncol 2012 Aug; 39(4): 369–373; doi: 10.1053/j.seminoncol.2012.05.007.
16. Peng ZW, Zhang YJ, Chen MS et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31: 426–432.
17. Burrel M, Reig M, Forner A et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 2012; 56(6): 1330–1335.
18. Lewandowski, RJ, Kulik LM, Riaz A et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant2009; 9(8): 1920–1928.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Pancreatic cancer – current effective diagnostic and therapeutic approach
- Malignant biliary obstruction
- Professor Josef Marek - octogenarian
- Population colorectal cancer screening in the Czech Republic